Drug Trial Radar · NCT05840016
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
532
Actual
Start
Aug 17, 2023
Primary completion
Feb 28, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.
Conditions
- Advanced Squamous Non Small Cell Lung Cancer
Interventions
AK112, Carboplatin, PaxlitaxelDrug
IV infusion,Specified dose on specified days
Tislelizumab, Carboplatin, PaxlitaxelDrug
IV infusion,Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS assessed by IRRC per RECIST v1.1Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.